NEURONTIN (gabapentin) by Viatris (2) is unknown. First approved in 2000.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
NEURONTIN (gabapentin) is an oral small-molecule anticonvulsant approved in 2000 with an unknown mechanism of action, though it binds to the α2δ subunit of voltage-activated calcium channels. It is indicated for neuropathic pain conditions and seizure management. The drug's mechanism remains incompletely understood despite decades of clinical use.
As LOE approaches, expect brand protection initiatives and cost-containment focus; team may consolidate around key accounts and managed care.
unknown. Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake, or degradation. In vitro studies have shown that gabapentin binds with high-affinity to the α2δ subunit of voltage-activated calcium channels; however, the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures
Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain
Worked on NEURONTIN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
NEURONTIN offers limited career momentum due to its LOE-approaching status and mature market position; roles focus on defending market share against generics and optimizing payer relationships rather than launching or expanding indication footprint. Career growth on this product is constrained compared to growth-stage assets, though experience in managed care and generic competition is valuable.